Press release
Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society
JDS conference seminars and information at the Dexcom booth will demonstrate Dexcom CGM is central to optimal diabetes management for people with both Type 1
About this update from Dexcom, Inc.
[{"type":"text","content":"\nJDS conference seminars and information at the Dexcom booth will demonstrate Dexcom CGM is central to optimal diabetes management for people with both Type 1 and Type 2 diabetes, including older adults\n\n\n KAGOSHIMA, Japan--(BUSINESS WIRE)--\nDexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM System and will highlight the latest clinical evidence that continues to demonstrate the effectiveness of Dexcom CGM during the 66th Annual Meeting of the Japan Diabetes Society held May 11-13, 2023 in Kagoshima, Japan.\n\n\nDexcom G6 uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device* or receiver, giving patients real-time glucose data without the need to scan or prick their finger.† The system has customizable and predictive alerts and alarms to help avoid potentially dangerous low and high blood sugar events and a function that allows patients to share their glucose data in real time with up to 10 followers.‡\n\n\n“Over the last several months we have made significant progress in making Dexcom G6 more accessible and easier to use for people living with diabetes in Japan,” said Scott Moss, vice president of Asia-Pacific at Dexcom. “Since the last annual JDS meeting, we have been able to secure a non-adjunctive indication for Dexcom G6, making it the only real-time CGM system in Japan that can be used to make treatment decisions without routine fingersticks.† Additionally, the Japanese Ministry of Health, Labour and Welfare recently approved the expansion of reimbursement coverage for Dexcom G6 to include all people with diabetes who use insulin at least once a day, making real-time CGM accessible to more than a million additional people living with diabetes in Japan.”\n\n\nBoth the non-adjunctive decision and the decision to expand reimbursement coverage were granted based on extensive research that demonstrates the accuracy, reliability, ease of use and clinical benefits of Dexcom G6.\n\n\nDexcom G6: Real-time glucose readings users can trust\n\n\n\nWith more than 300 clinical trials, the accuracy and efficacy of Dexcom CGM is supported by more peer reviewed research than any other CGM system on the market1-13\n\n\n\nTy...